BioteBTMD -6.67%70 EBITDA Margin % is 14.00% as of Mar. 2026, which is 37% below its 10-year median of 22.09. GuruFocus rates BTMD with a GF Score™ of 70/100 and a GF Value™ of $3.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Biote ranks better than 74.25% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Biote's EBITDA for the
three
months ended in Mar. 2026 was $6.3 Mil. Biote's Revenue for the
three
months ended in Mar. 2026 was $44.9 Mil. Therefore, Biote's EBITDA margin for the quarter that ended in Mar. 2026 was 14.00%.
Biote (NAS:BTMD) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Biote EBITDA Margin % Related Terms
Biote EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Biote's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BTMD vs DCGO, PIII, PARK: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Biote's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biote EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Biote's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Biote's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biote (BTMD) has a EBITDA Margin % of 14.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biote and its competitors. This is 37% below median its historical median of 22.09. Over the past decade, Biote's EBITDA Margin % has ranged from 4.82 to 28.24. According to the industry distribution chart, Biote ranks #172 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 25.7%.
Is Biote's EBITDA Margin % too high?
Biote's current EBITDA Margin % of 14.00% is 37% below median its 10-year median of 22.09. Over the past 10 years, this metric has ranged from a low of 4.82 to a high of 28.24. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Biote's value of 14.00% is 37.1% above this industry median. Based on the distribution chart, Biote ranks #172 out of 668 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Biote has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biote's EBITDA Margin % compare to DCGO and PIII?
According to the Healthcare Providers & Services industry distribution chart, Biote ranks #172 out of 668 companies for EBITDA Margin %. This puts Biote in the upper half of its industry. The industry median EBITDA Margin % is 10.21. Biote's value of 14.00% is 37.1% above this benchmark. Historically, Biote's own EBITDA Margin % has ranged from 4.82 to 28.24 over the past decade. While the company's 10-year median is 22.09 vs. the industry median of 10.21, Biote has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biote's current EBITDA Margin % of 14.00% is 37.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biote and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biote's current EBITDA Margin % is 14.00%, which is 37% below median its own 10-year median of 22.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biote stock overvalued right now?
Based on GuruFocus' analysis, Biote (BTMD) is currently considered Significantly Undervalued. The stock's GF Value™ is $3.07, compared to a current price of $1.95 — trading 36.5% below its estimated fair value. The current EBITDA Margin % is 14.00%, which is 37% below median its 10-year median of 22.09 and 37.1% above the Healthcare Providers & Services industry median of 10.21. Biote's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Biote (BTMD), the current EBITDA Margin % is 14.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biote (BTMD) Overvalued in 2026?
Based on GuruFocus' analysis, Biote stock appears to be undervalued.
The current stock price of $1.95 is trading 36.5% below its estimated GF Value™ of $3.07.
GuruFocus considers Biote to be Significantly Undervalued.
Key valuation signals for BTMD:
EBITDA Margin %: 14.00% (37% below median its 10-year median of 22.09)
GF Value™: $3.07 vs. price of $1.95 (36.5% below fair value)
Industry Position: 37.1% above the Healthcare Providers & Services median (#172 of 668)
No single metric tells the full story. See the BTMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
70GF Score
Get the complete analysis for BTMD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTMD has been successfully added to your 
